Double Trouble: Coronavirus Disease 2019 with Lupus Flare

Rashmi Joshi; Aravind Sekar; Aman Sharma; Sreedhara B Chaluvashetty; Mini P Singh; Amanjit Bal; Ritambhra Nada

doi:10.5005/jp-journals-11006-0078

SEARCH WITHIN CONTENT

Online First

Double Trouble: Coronavirus Disease 2019 with Lupus Flare

Rashmi Joshi, Aravind Sekar, Aman Sharma, Sreedhara B Chaluvashetty, Mini P Singh, Amanjit Bal, Ritambhra Nada

Keywords : Autopsy, Coronavirus disease 2019, Diffuse alveolar damage, Diffuse alveolar hemorrhage, Systemic lupus erythematosus

Citation Information : Joshi R, Sekar A, Sharma A, Chaluvashetty SB, Singh MP, Bal A, Nada R. Double Trouble: Coronavirus Disease 2019 with Lupus Flare. 2023; 2 (5):117-123.

DOI: 10.5005/jp-journals-11006-0078

License: CC BY-NC 4.0

Published Online: 27-10-2023

ARTICLE
REFERENCES

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the coronavirus disease (COVID-19) pandemic, with over 65 million deaths worldwide. Clinical manifestations of COVID-19 varied from asymptomatic to severe acute respiratory distress syndrome. The exact incidence of COVID-19 in lupus patients is not known. However, studies have shown that lupus patients might be more prone to SARS-CoV-2 infection and may have severe clinical manifestations due to aberrant baseline inflammation and dysregulated immune responses. Further, the immunosuppressive treatment that lupus patients receive also compromises their immunity and paves the way for infection. We intend to present the complete clinical and autopsy findings of a 28-year-old female who presented with lupus flares involving major organs and acquired COVID-19 infection during treatment. Subsequently, there was worsening respiratory failure, and she finally succumbed to death despite all supportive measures.

HTML PDF Share

Petri M, Singh S, Tesfasyone H, et al. Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study. J Rheumatol 2009;36(11): 2476–2480. DOI: 10.3899/jrheum.090019
Conti F, Ceccarelli F, Perricone C, et al. Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study. PLoS One 2012;7(9):e45934. DOI: 10.1371/journal.pone.0045934
Nikpour M, Urowitz MB, Ibañez D, et al. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum 2009;61(9):1152–1158. DOI: 10.1002/art.24741
Alharthy A, Faqihi F, Nasim N, et al. COVID-19 in a patient with a flare of systemic lupus erythematosus: a rare case-report. Respir Med Case Rep 2020;31:101252. DOI: 10.1016/j.rmcr.2020.101252
Bozzalla Cassione E, Zanframundo G, Biglia A, et al. COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine. Ann Rheum Dis 2020;79(10):1382–1383. DOI: 10.1136/annrheumdis-2020-217717
Martin M, Guffroy A, Argemi X, et al. [Systemic lupus erythematosus and lymphopenia: Clinical and pathophysiological features]. Rev Med Interne 2017;38(9):603–613. DOI: 10.1016/j.revmed.2017.01.005
Bhatnagar J, Gary J, Reagan-Steiner S, et al. Evidence of severe acute respiratory syndrome coronavirus 2 replication and tropism in the lungs, airways, and vascular endothelium of patients with fatal coronavirus disease 2019: an autopsy case series. J Infect Dis 2021;223(5):752–764. DOI: 10.1093/infdis/jiab039

PDF Share